X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisiton, Vertex expand its immunology portfolio by including Alpine’s ALPN-303 (povetacicept), is a highly potent and effective dual antagonist of BAFF and APRIL. Currently it is on track to enter late stage trial in second half of 2024 for the treatment of IgA nephropathy.
Lead Product(s): Povetacicept
Therapeutic Area: Nephrology Product Name: ALPN-303
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Alpine Immune Sciences
Deal Size: $4,900.0 million Upfront Cash: $4,900.0 million
Deal Type: Acquisition April 10, 2024
Details:
VX-147 (inaxaplin) is an oral, small-molecule inhibitor of APOL1 channel function, which is being evaluated for the treatment of APOL1-mediated kidney disease.
Lead Product(s): Inaxaplin
Therapeutic Area: Nephrology Product Name: VX-147
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
VX-407 is a first-in-class small molecule corrector that is designed to inhibit PKD1. It is being evaluated for the treatment of autosomal dominant polycystic kidney disease.
Lead Product(s): VX-407
Therapeutic Area: Genetic Disease Product Name: VX-407
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Kalydeco (ivacaftor) is an oral, CFTR potentiator, small molecule drug candidate. It is being evaluated for the treatment of cystic fibrosis in patients aged 1 month and older.
Lead Product(s): Ivacaftor
Therapeutic Area: Genetic Disease Product Name: Kalydeco
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Casgevy (exagamglogene autotemcel) is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is indicated for patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: Casgevy
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Lead Product(s): Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area: Genetic Disease Product Name: VX-121
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
VX-548 (suzetrigine) is a selective NaV1.8 inhibitor, which is being evaluated in phase 3 clinical trials for the treatment of moderate-to-severe acute pain.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Product Name: VX-548
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
Casgevy (exagamglogene autotemcel) is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Genetic Disease Product Name: Casgevy
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: CRISPR Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Casgevy (exagamglogene autotemcel) is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is indicated for patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: Casgevy
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
Under the agreement, Charles River will manufacture Vertex’s CASGEVY (exagamglogene autotemcel) therapy, the world’s first gene-edited therapy targeting severe sickle cell disease.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: Casgevy
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Charles River Laboratories, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
